Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients for National Security

By the authority vested in me as President by the Constitution and the laws of the United States of America, including but not limited to section 232 of the Trade Expansion Act of 1962, as amended (19 U.S.C. 1862), I hereby proclaim that the quantity of pharmaceuticals and active pharmaceutical ingredients imported into the United States presents a threat to national security by impairing the ability to mobilize the defense industrial base during emergencies, as determined by the Secretary of Commerce after investigation. To address this threat, effective 30 days after publication in the Federal Register, the Harmonized Tariff Schedule of the United States (HTS) is modified to impose a 25 percent ad valorem duty on HTS headings covering pharmaceuticals (Chapter 30) and key active pharmaceutical ingredients (specific subheadings identified in Annex A), excluding allies under free trade agreements. Imports from Canada and Mexico under USMCA remain exempt to preserve North American integration. This adjustment shall sunset after 5 years unless extended by subsequent proclamation following a new Commerce Department review and congressional notification. The Secretary of Commerce shall submit quarterly reports on implementation, domestic production impacts, and supply effects to the Senate Committee on Finance and House Committee on Ways and Means. U.S. Customs and Border Protection shall enforce these duties, with importers eligible for exclusions via petition to Commerce. This proclamation promotes Article I, Section 8, Clause 3 commerce regulation through delegated executive action while reserving congressional oversight.